|
Thursday 14th September 2023 |
Text too small? |
Cannasouth Limited (NZX: CBD ) has exported to Australia its first commercial shipment of its high-purity cannabidiol (CBD) isolate, a cannabis-based, active pharmaceutical ingredient (API). This is a first for Aotearoa New Zealand’s medicinal cannabis industry.
This CBD isolate was manufactured in New Zealand to PIC/s Good Manufacturing Practice (GMP) standards and verified by the Medicinal Cannabis Agency. This first shipment is the forerunner of greater volumes of API exports for the local industry, signalling the demand for high-quality, GMP certified cannabis-based APIs on the international stage.
This signals the next growth phase for Cannasouth and the medicinal cannabis industry.
-ENDS-
No comments yet
BPG - Q1 FY27 Trading Update
AFT R&D Portfolio Offers Multi-$bn Market Potential
BRW - Chief Executive Officer
SPK-30 advanced with strategic review of Digital Services
FPH 2026 Notice of Annual Meeting and Voting Form
CNU - Q4 FY26 Connections Update
SPK - Spark announces appointment of Chief Operating Officer
SKC - Asset Monetisation Programme Update - The Grand Hotel
VCT - Full year results date & investor webcast details
ANZ - Air New Zealand 2026 Annual Results Webcast Details